Prescribing prevalence, effectiveness, and mental health safety of smoking cessation medicines in patients with mental disorders

Gemma Taylor, Taha Itani, Kyla H Thomas, Dheeraj Rai, Tim Jones, Frank Windmeijer, Richard Martin, Marcus R Munafò, Neil M. Davies, Amy E. Taylor

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: We conducted a prospective cohort study of the Clinical Practice Research Database to estimate rates of varenicline and nicotine replacement therapy (NRT) prescribing and the relative effects on smoking cessation, and mental health. METHODS: We used multivariable logistic regression, propensity score matched regression, and instrumental variable analysis. Exposure was varenicline or NRT prescription. Mental disorders were bipolar, depression, neurotic disorder, schizophrenia, or prescriptions of antidepressants, antipsychotics, hypnotics/anxiolytics, mood stabilizers. Outcomes were smoking cessation, and incidence of neurotic disorder, depression, prescription of antidepressants, or hypnotics/anxiolytics. Follow-ups were 3, 6, and 9 months, and at 1, 2, and 4 years. RESULTS: In all patients, NRT and varenicline prescribing declined during the study period. Seventy-eight thousand four hundred fifty-seven smokers with mental disorders aged ≥18 years were prescribed NRT (N = 59 340) or varenicline (N = 19 117) from September 1, 2006 to December 31, 2015. Compared with smokers without mental disorders, smokers with mental disorders had 31% (95% CI: 29% to 33%) lower odds of being prescribed varenicline relative to NRT, but had 19% (95% CI: 15% to 24%) greater odds of quitting at 2 years when prescribed varenicline relative to NRT. Overall, varenicline was associated with decreased or similar odds of worse mental health outcomes than NRT in patients both with and without mental disorders, although there was some variation when analyses were stratified by mental disorder subgroup. CONCLUSIONS: Smoking cessation medication prescribing may be declining in primary care. Varenicline was more effective than NRT for smoking cessation in patients with mental disorders and there is not clear consistent evidence that varenicline is adversely associated with poorer mental health outcomes. IMPLICATIONS: Patients with mental disorders were less likely to be prescribed varenicline than NRT. We triangulated results from three analytical techniques. We found that varenicline was more effective than NRT for smoking cessation in patients with mental disorders. Varenicline was generally associated with similar or decreased odds of poorer mental health outcomes (ie, improvements in mental health) when compared with NRT. We report these findings cautiously as our data are observational and are at risk of confounding.
Original languageEnglish
Article numberntz072
Pages (from-to)48-57
JournalNicotine & Tobacco Research
Volume22
Issue number1
Early online date10 Jul 2019
DOIs
Publication statusPublished - 31 Jan 2020

Keywords

  • varenicline
  • nicotine replacement therapy
  • mental health
  • smoking cessation
  • instrumental variable analyses
  • propensity score matching
  • triangulation
  • CPRD
  • primary care

Cite this

Prescribing prevalence, effectiveness, and mental health safety of smoking cessation medicines in patients with mental disorders. / Taylor, Gemma; Itani, Taha; Thomas, Kyla H; Rai, Dheeraj ; Jones, Tim ; Windmeijer, Frank; Martin, Richard; Munafò, Marcus R; Davies, Neil M.; Taylor, Amy E.

In: Nicotine & Tobacco Research, Vol. 22, No. 1, ntz072, 31.01.2020, p. 48-57.

Research output: Contribution to journalArticle

Taylor, G, Itani, T, Thomas, KH, Rai, D, Jones, T, Windmeijer, F, Martin, R, Munafò, MR, Davies, NM & Taylor, AE 2020, 'Prescribing prevalence, effectiveness, and mental health safety of smoking cessation medicines in patients with mental disorders', Nicotine & Tobacco Research, vol. 22, no. 1, ntz072, pp. 48-57. https://doi.org/10.1093/ntr/ntz072
Taylor, Gemma ; Itani, Taha ; Thomas, Kyla H ; Rai, Dheeraj ; Jones, Tim ; Windmeijer, Frank ; Martin, Richard ; Munafò, Marcus R ; Davies, Neil M. ; Taylor, Amy E. / Prescribing prevalence, effectiveness, and mental health safety of smoking cessation medicines in patients with mental disorders. In: Nicotine & Tobacco Research. 2020 ; Vol. 22, No. 1. pp. 48-57.
@article{f6628da9c3ad44edb23ddb5b9758aa34,
title = "Prescribing prevalence, effectiveness, and mental health safety of smoking cessation medicines in patients with mental disorders",
abstract = "OBJECTIVE: We conducted a prospective cohort study of the Clinical Practice Research Database to estimate rates of varenicline and nicotine replacement therapy (NRT) prescribing and the relative effects on smoking cessation, and mental health. METHODS: We used multivariable logistic regression, propensity score matched regression, and instrumental variable analysis. Exposure was varenicline or NRT prescription. Mental disorders were bipolar, depression, neurotic disorder, schizophrenia, or prescriptions of antidepressants, antipsychotics, hypnotics/anxiolytics, mood stabilizers. Outcomes were smoking cessation, and incidence of neurotic disorder, depression, prescription of antidepressants, or hypnotics/anxiolytics. Follow-ups were 3, 6, and 9 months, and at 1, 2, and 4 years. RESULTS: In all patients, NRT and varenicline prescribing declined during the study period. Seventy-eight thousand four hundred fifty-seven smokers with mental disorders aged ≥18 years were prescribed NRT (N = 59 340) or varenicline (N = 19 117) from September 1, 2006 to December 31, 2015. Compared with smokers without mental disorders, smokers with mental disorders had 31{\%} (95{\%} CI: 29{\%} to 33{\%}) lower odds of being prescribed varenicline relative to NRT, but had 19{\%} (95{\%} CI: 15{\%} to 24{\%}) greater odds of quitting at 2 years when prescribed varenicline relative to NRT. Overall, varenicline was associated with decreased or similar odds of worse mental health outcomes than NRT in patients both with and without mental disorders, although there was some variation when analyses were stratified by mental disorder subgroup. CONCLUSIONS: Smoking cessation medication prescribing may be declining in primary care. Varenicline was more effective than NRT for smoking cessation in patients with mental disorders and there is not clear consistent evidence that varenicline is adversely associated with poorer mental health outcomes. IMPLICATIONS: Patients with mental disorders were less likely to be prescribed varenicline than NRT. We triangulated results from three analytical techniques. We found that varenicline was more effective than NRT for smoking cessation in patients with mental disorders. Varenicline was generally associated with similar or decreased odds of poorer mental health outcomes (ie, improvements in mental health) when compared with NRT. We report these findings cautiously as our data are observational and are at risk of confounding.",
keywords = "varenicline, nicotine replacement therapy, mental health, smoking cessation, instrumental variable analyses, propensity score matching, triangulation, CPRD, primary care",
author = "Gemma Taylor and Taha Itani and Thomas, {Kyla H} and Dheeraj Rai and Tim Jones and Frank Windmeijer and Richard Martin and Munaf{\`o}, {Marcus R} and Davies, {Neil M.} and Taylor, {Amy E.}",
year = "2020",
month = "1",
day = "31",
doi = "10.1093/ntr/ntz072",
language = "English",
volume = "22",
pages = "48--57",
journal = "Nicotine & Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Prescribing prevalence, effectiveness, and mental health safety of smoking cessation medicines in patients with mental disorders

AU - Taylor, Gemma

AU - Itani, Taha

AU - Thomas, Kyla H

AU - Rai, Dheeraj

AU - Jones, Tim

AU - Windmeijer, Frank

AU - Martin, Richard

AU - Munafò, Marcus R

AU - Davies, Neil M.

AU - Taylor, Amy E.

PY - 2020/1/31

Y1 - 2020/1/31

N2 - OBJECTIVE: We conducted a prospective cohort study of the Clinical Practice Research Database to estimate rates of varenicline and nicotine replacement therapy (NRT) prescribing and the relative effects on smoking cessation, and mental health. METHODS: We used multivariable logistic regression, propensity score matched regression, and instrumental variable analysis. Exposure was varenicline or NRT prescription. Mental disorders were bipolar, depression, neurotic disorder, schizophrenia, or prescriptions of antidepressants, antipsychotics, hypnotics/anxiolytics, mood stabilizers. Outcomes were smoking cessation, and incidence of neurotic disorder, depression, prescription of antidepressants, or hypnotics/anxiolytics. Follow-ups were 3, 6, and 9 months, and at 1, 2, and 4 years. RESULTS: In all patients, NRT and varenicline prescribing declined during the study period. Seventy-eight thousand four hundred fifty-seven smokers with mental disorders aged ≥18 years were prescribed NRT (N = 59 340) or varenicline (N = 19 117) from September 1, 2006 to December 31, 2015. Compared with smokers without mental disorders, smokers with mental disorders had 31% (95% CI: 29% to 33%) lower odds of being prescribed varenicline relative to NRT, but had 19% (95% CI: 15% to 24%) greater odds of quitting at 2 years when prescribed varenicline relative to NRT. Overall, varenicline was associated with decreased or similar odds of worse mental health outcomes than NRT in patients both with and without mental disorders, although there was some variation when analyses were stratified by mental disorder subgroup. CONCLUSIONS: Smoking cessation medication prescribing may be declining in primary care. Varenicline was more effective than NRT for smoking cessation in patients with mental disorders and there is not clear consistent evidence that varenicline is adversely associated with poorer mental health outcomes. IMPLICATIONS: Patients with mental disorders were less likely to be prescribed varenicline than NRT. We triangulated results from three analytical techniques. We found that varenicline was more effective than NRT for smoking cessation in patients with mental disorders. Varenicline was generally associated with similar or decreased odds of poorer mental health outcomes (ie, improvements in mental health) when compared with NRT. We report these findings cautiously as our data are observational and are at risk of confounding.

AB - OBJECTIVE: We conducted a prospective cohort study of the Clinical Practice Research Database to estimate rates of varenicline and nicotine replacement therapy (NRT) prescribing and the relative effects on smoking cessation, and mental health. METHODS: We used multivariable logistic regression, propensity score matched regression, and instrumental variable analysis. Exposure was varenicline or NRT prescription. Mental disorders were bipolar, depression, neurotic disorder, schizophrenia, or prescriptions of antidepressants, antipsychotics, hypnotics/anxiolytics, mood stabilizers. Outcomes were smoking cessation, and incidence of neurotic disorder, depression, prescription of antidepressants, or hypnotics/anxiolytics. Follow-ups were 3, 6, and 9 months, and at 1, 2, and 4 years. RESULTS: In all patients, NRT and varenicline prescribing declined during the study period. Seventy-eight thousand four hundred fifty-seven smokers with mental disorders aged ≥18 years were prescribed NRT (N = 59 340) or varenicline (N = 19 117) from September 1, 2006 to December 31, 2015. Compared with smokers without mental disorders, smokers with mental disorders had 31% (95% CI: 29% to 33%) lower odds of being prescribed varenicline relative to NRT, but had 19% (95% CI: 15% to 24%) greater odds of quitting at 2 years when prescribed varenicline relative to NRT. Overall, varenicline was associated with decreased or similar odds of worse mental health outcomes than NRT in patients both with and without mental disorders, although there was some variation when analyses were stratified by mental disorder subgroup. CONCLUSIONS: Smoking cessation medication prescribing may be declining in primary care. Varenicline was more effective than NRT for smoking cessation in patients with mental disorders and there is not clear consistent evidence that varenicline is adversely associated with poorer mental health outcomes. IMPLICATIONS: Patients with mental disorders were less likely to be prescribed varenicline than NRT. We triangulated results from three analytical techniques. We found that varenicline was more effective than NRT for smoking cessation in patients with mental disorders. Varenicline was generally associated with similar or decreased odds of poorer mental health outcomes (ie, improvements in mental health) when compared with NRT. We report these findings cautiously as our data are observational and are at risk of confounding.

KW - varenicline

KW - nicotine replacement therapy

KW - mental health

KW - smoking cessation

KW - instrumental variable analyses

KW - propensity score matching

KW - triangulation

KW - CPRD

KW - primary care

U2 - 10.1093/ntr/ntz072

DO - 10.1093/ntr/ntz072

M3 - Article

VL - 22

SP - 48

EP - 57

JO - Nicotine & Tobacco Research

JF - Nicotine & Tobacco Research

SN - 1462-2203

IS - 1

M1 - ntz072

ER -